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Abstract
Background: No mortality prediction rule is suited for non-elderly patients with community-acquired pneumonia.
Therefore, we tried to create a mortality prediction rule that is simple and suitable for non-elderly patients with
community-acquired pneumonia.
Methods: Because of low mortality at young age, we used information from an administrative database that included
A-DROP data. We analysed the rate and risk factors for in-hospital community-acquired pneumonia-associated death
among non-elderly patients and created a mortality prediction rule based on those risk factors.
Results: We examined 49,370 hospitalisations for patients aged 18–64 years with community-acquired pneumonia.
The 30-day fatality rate was 1.5 %. Using regression analysis, five risk factors were selected: patient requires help for
feeding, the existence of malignancy, confusion, low blood pressure, and age 40–64 years. Each risk factor of our
proposed mortality risk scoring system received one point. A total point score for each patient was obtained by
summing the points. The negative likelihood ratio for the score 0 group was 0.01, and the positive likelihood ratio
for the score ≥4 group was 19.9. The area under the curve of the risk score for non-elderly (0.86, 95 % confidence
interval: 0.84–0.87) was higher than that of the A-DROP score (0.72, 95 % confidence interval: 0.70–0.74) (P < 0.0001).
Conclusions: Our newly proposed mortality risk scoring system may be appropriate for predicting mortality in
non-elderly patients with community-acquired pneumonia. It showed a possibility of a better prediction value
than the A-DROP and is easy to use in various clinical settings.
Keywords: Clinical prediction rule, Mortality, Pneumonia, Young adult, Middle aged
Background
Community-acquired pneumonia (CAP) remains a major
cause of death for elderly and non-elderly people [1–4].
Particularly, in younger and middle-aged adults, most of
whom are working-age adults, productivity losses due to
death caused by CAP are an important problem from an
economic and medical expenses standpoint [4]. It is also
important to distinguish patients who are at low risk to
prevent over-treatment, because there is a tendency to
overestimate the risk of death in patients with CAP [5].
However, few studies have attempted to distinguish low-
risk CAP patients from high risk ones and determine
which patients would benefit when treated as outpatients.
Because of these reasons, a precise prediction rule for
identifying the severity of CAP is required, especially for
non-elderly patients.
There are various indexes for estimating the severity
of CAP patients [5–13]. Of those, the most common is
the pneumonia severity index (PSI) and the CURB-65
score [9]. However, it is unknown whether both can
correctly estimate the severity of CAP in non-elderly
patients, because in previous studies, most patients have
been elderly [14–19]. Therefore, our study aimed to
create a mortality prediction rule suitable for non-
elderly patients with CAP. Because of low morbidity and
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mortality at young age, we used information from an
administrative database that included A-DROP data.
Methods
Data source and patient selection
We used a nationwide dataset available through the
Japanese Diagnosis Procedure Combination (DPC) sys-
tem [20]. This dataset was collected by our survey of
DPC hospitals, which voluntarily participated with non-
disclosure agreement. Public access to the DPC database
was not permitted because it was private database of our
study group. The DPC database includes claims and
abstract discharge data for all inpatients discharged
from >1,000 participating hospitals in Japan. We anon-
ymised the data used upon extraction from the DPC
database and analysed it within the protected environ-
ment of the Nagasaki University Hospital. Informed
consent was not required for this study, and the institu-
tional review board of the Nagasaki University Hospital
(Nagasaki, Japan) approved the study design (Institutional
Review Board No. 15022334).
The present study used data collected from January
2010 to December 2012. Patients’ ages were 18–64 years
[2]. CAP was defined as the final diagnosis at hospital
discharge by the International Classification of Diseases,
tenth revision codes (ICD-10): J10-J18 (pneumonia) and
J69 (aspiration pneumonia) [2]. We excluded patients who
had any missing data from the statistical analyses.
Data extraction
The following characteristics for each patient were ex-
tracted: age; sex; height; weight; final diagnosis; comor-
bidities on admission with ICD-10 codes; smoking
status; Barthel index at admission, including the results
of each item; pneumonia severity; length of stay; and
death occurring within 30 days of hospital admission. In
this study, there were no data after patients’ discharge.
Comorbidities were evaluated using the Charlson index
and the presence of each item [21]. The Charlson index
includes seventeen conditions with major impact on sur-
vival described as Table 1. For each condition, between
one and six points are awarded and summed up for the
summary score. Higher score indicate severe comorbidi-
ties [22]. The Barthel index is a 10-item measure of
activities, such as feeding, moving from a wheelchair to
bed and back, personal grooming (washing and shaving
face, and combing hair), transferring to and from a toi-
let, bathing (patient can use a bath tub, a shower, or take
a complete sponge bath), walking on a level surface, as-
cending and descending stairs, dressing, and controlling
bowels and bladder [23, 24]. Those were scored according
to assistance required by the patient (Additional file 1:
Table S1). The total score was from 0–100 with lower
scores representing greater nursing dependency. The
pneumonia severity was evaluated using the A-DROP sys-
tem, which is the modified CURB-65 scoring system pro-
posed by The Japanese Respiratory Society. It assesses
Age, Dehydration (existence of a clinical sign of dehydra-
tion or blood urea nitrogen level ≥210 mg/L), Respiratory
failure (SpO2 ≤ 90 % or PaO2 ≤ 60 mmHg), Orientation
disturbance (confusion), and a low blood Pressure (systolic
blood pressure ≤90 mmHg) [25]. The scoring system
stratifies patients into four severity classes (mild = 0;
moderate = 1–2; severe = 3; and extremely severe = 4–5),
and it has an equal ability for predicting the mortality of
CAP compared to the CURB-65 scoring system [6]. In this
study, the score for age was 0 points in all patients be-
cause all were <65 years.
In addition to patients’ characteristics, we extracted
other factors that may be associated with mortality such
as health care region organisational factors, which in-
cluded the hospital volume, distance from patients’ home
to the hospital, weekend or holiday admission, and inten-
sive care unit admission [26–29].
Statistical analyses
We used standard deviations in our analyses. To examine
differences in characteristics among groups, Fisher’s exact
test or Pearson’s chi-square test was used to analyse
discrete variables, and the Wilcoxon rank sum test was
used for continuous variables. The health care region or-
ganisational factors were examined for association with
CAP mortality by using univariable and multivariable
logistic regression analyses. Odds ratios (ORs) and their
95 % confidence intervals (CIs) were calculated. Statistical
analyses were performed using JMP 11.2 software (SAS
Institute, Cary, NC, USA). All tests were two-tailed, and a
P-value <0.05 was considered statistically significant.
To determine the order of importance of factors pre-
dicting 30-day case fatality, we conducted a forward
stepwise selection of the factors. The sources of selected
factors were the demographics, comorbidities, Barthel
index items, parameters of the A-DROP (confusion, de-
hydration, respiratory failure, and low blood pressure),
and health care region organisation. Scores of the Charlson
comorbidity and Barthel indices were excluded; alterna-
tively, a particular item of each index was used because
calculation of those indexes is difficult in busy clinical
settings. Based on the stepwise selection of factors and
from a standpoint of ease of use, we selected five items
for predicting 30-day mortality. Each risk factor of our
proposed mortality risk scoring system received one
point. A total point score for each patient was obtained
by summing the points. The validity of the new predic-
tion rule compared to the A-DROP system for CAP
mortality was evaluated using the receiver operating
characteristics (ROC) curve, Kaplan-Meier survival
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Table 1 Baseline characteristics and mortality of the study cohort
Characteristic No. of cases (%) No. (%) of cases alive at 30 days No. (%) of cases that
died within 30 days
(n = 49,370) (n = 48,638) (n = 732)
Sex
Male 28,070 (56.9) 27,550 (56.6) 520 (71.0)
Female 21,300 (43.1) 21,088 (43.4) 212 (29.0)
Age, years
18–39 14,791 (30.0) 14,753 (30.3) 38 (5.2)
40–49 7,167 (14.5) 7,106 (14.6) 61 (8.3)
50–64 27,412 (55.5) 26,779 (55.1) 633 (86.5)
Body mass index (kg/m2)
≤ 15 2,485 (5.0) 2,360 (4.9) 125 (17.1)
16–29 44,419 (90.0) 43,834 (90.1) 585 (79.9)
≥ 30 2,466 (5.0) 2,444 (5.0) 22 (3.0)
Smoking status
Never smoked 27,883 (56.5) 27,506 (56.6) 377 (51.5)
Current/ex-smoker 21,487 (43.5) 21,132 (43.4) 355 (48.5)
Charlson comorbidity index
0–1 37,642 (76.2) 37,269 (76.6) 373 (51.0)
2–4 10,534 (21.3) 10,270 (21.1) 264 (36.1)
≥ 5 1,194 (2.4) 1,099 (2.3) 95 (13.0)
Myocardial infarction 330 (0.7) 324 (0.7) 6 (0.8)
Congestive heart failure 2,667 (5.4) 2,572 (5.3) 95 (13.0)
Peripheral vascular disease 264 (0.5) 259 (0.5) 5 (0.7)
Cerebrovascular diseases 1,497 (3.0) 1,458 (3.0) 39 (5.3)
Dementia 201 (0.4) 192 (0.4) 9 (1.2)
Chronic pulmonary disease 8,503 (17.2) 8,426 (17.3) 77 (10.5)
Rheumatic disease 1,854 (3.8) 1,818 (3.7) 36 (4.9)
Peptic ulcer disease 1,910 (3.9) 1,886 (3.9) 24 (3.3)
Mild liver disease 2,464 (5.0) 2,435 (5.0) 29 (4.0)
Diabetes without chronic complications 4,741 (9.6) 4,647 (9.6) 94 (12.8)
Diabetes with chronic complications 1,587 (3.2) 1,547 (3.2) 40 (5.5)
Hemiplegia or paraplegia 154 (0.3) 153 (0.3) 1 (0.1)
Renal disease 1,490 (3.0) 1,444 (3.0) 46 (6.3)
Any malignancy 4,364 (8.8) 4,218 (8.7) 146 (19.9)
Moderate or severe liver disease 61 (0.1) 56 (0.1) 5 (0.7)
Metastatic solid tumour 860 (1.7) 777 (1.6) 83 (11.3)
AIDS/HIV 81 (0.2) 80 (0.2) 1 (0.1)
Barthel index (score)
81–100 37,035 (75.0) 36,848 (75.8) 187 (25.5)
41–80 4,733 (9.6) 4,644 (9.5) 89 (12.2)
0–40 7,602 (15.4) 7,146 (14.7) 456 (62.3)
Requires help with
Feeding 8,928 (18.1) 8,448 (17.4) 480 (65.6)
Moving from the wheelchair to the bed 12,367 (25.0) 11,832 (24.3) 535 (73.1)
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curves, and log-rank analyses. Overall, the model pre-
diction was expressed as a c statistic [2, 30].
Results
Baseline characteristics and mortality
There were 77,819 hospitalised patients with CAP, among
which 28,849 patients’ data were incomplete. Therefore,
we analysed the remaining 49,370 hospitalisations of pa-
tients aged 18–64 years with CAP. Table 1 shows the
baseline characteristics. The 30-day case-fatality rate was
1.5 %. The percentage of patients who died was higher
among men than women (P < 0.0001). An older age, high
Charlson comorbidity index, low Barthel index, and high
severity of pneumonia were associated with a higher mor-
tality (P < 0.0001, all). Body mass index was also associated
with CAP mortality (P < 0.0001), particularly in thin
patients with a body mass index <15 kg/m2 (30-day mor-
tality: 5.0 %).
As observed in the pneumonia aetiology, aspiration
pneumonia had the highest in-hospital mortality (4.5 %),
followed by influenza pneumonia (1.8 %) (Table 2). The
lowest mortality was observed for mycoplasmal pneu-
monia (0.1 %).
Health care region organisational factors
Table 3 shows the association between the CAP mortality
of non-elderly patients and the health care region organ-
isational factors. As observed in the results of crude ORs,
the risk of 30-day mortality was higher in patients who
were admitted to a high volume hospital, whose homes
Table 2 Pneumonia characteristics and mortality
Characteristic No. of cases (%) No. (%) of cases alive at 30 days No. (%) of cases that died
within 30 days
(n = 49,370) (n = 48,638) (n = 732)
Parameters of the A-DROPa
Confusion 927 (1.9) 832 (1.7) 95 (13.0)
Dehydration 3,390 (6.9) 3,255 (6.7) 135 (18.4)
Respiratory failure 3,940 (8.0) 3,779 (7.8) 161 (22.0)
Low blood pressure 6,697 (13.6) 6,353 (13.1) 344 (47.0)
Pneumonia severityb
Mild 37,094 (75.1) 36,845 (75.8) 249 (34.0)
Moderate 11,712 (23.7) 11,308 (23.2) 404 (55.2)
Severe 411 (0.8) 367 (0.8) 44 (6.0)
Extremely severe 153 (0.3) 118 (0.2) 35 (4.8)
Pneumonia aetiology
Pneumococcal 4,392 (8.9) 4,361 (9.0) 31 (4.2)
Mycoplasmal 5,010 (10.1) 5,004 (10.3) 6 (0.8)
Aspiration 3,586 (7.3) 3,425 (7.0) 161 (22.0)
Influenza 167 (0.3) 164 (0.3) 3 (0.4)
Othersc 36,215 (73.4) 35,684 (73.4) 531 (72.5)
aA-DROP assesses confusion, dehydration (the existence of a clinical sign of dehydration or blood urea nitrogen level ≥210 mg/L), respiratory failure (SpO2 ≤ 90 %
or PaO2 ≤ 60 mmHg), and a low blood pressure (systolic blood pressure ≤90 mmHg). Age was excluded from this table because all patients were <65 years
bThe pneumonia severity was evaluated using the A-DROP scoring system. Scoring: 0 =mild, 1–2 =moderate, 3 = severe, and 4 = extremely severe
cThis group includes other bacterial or viral and unspecified bacterial pneumonia
Table 1 Baseline characteristics and mortality of the study cohort (Continued)
Personal grooming 9,842 (19.9) 9,345 (19.2) 497 (67.9)
Getting on/off toilet 10,869 (22.0) 10,345 (21.3) 524 (71.6)
Bathing 12,610 (25.5) 12,065 (24.8) 545 (74.5)
Walking on a level surface 12,581 (25.5) 12,035 (24.7) 546 (74.6)
Ascending and descending stairs 13,433 (27.2) 12,872 (26.5) 561 (76.6)
Dressing 12,572 (25.5) 12,032 (24.7) 540 (73.8)
Controlling the bowels 8,313 (16.8) 7,844 (16.1) 469 (64.1)
Controlling the bladder 8,377 (17.0) 7,906 (16.3) 471 (64.3)
Definition of abbreviations: AIDS acquired immune deficiency syndrome, HIV human immunodeficiency virus
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were far from the hospital, and who were admitted on
weekends or holidays. However, the pneumonia severity
was also higher in patients with those factors. Therefore,
the adjusted ORs showed no significant difference for
those factors.
Newly proposed mortality prediction rule
Stepwise analysis selected the following factors for pre-
dicting 30-day mortality: age 40–49 years, age 50–64
years, body mass index ≤15 kg/m2, congestive heart failure,
cerebrovascular diseases, any malignancy, metastatic solid
tumour, patients requiring help with feeding, patients re-
quiring help ascending and descending stairs, control of
the bowels, respiratory failure, confusion, and low blood
pressure. Among them, we carefully selected five factors in
terms of ease of use and degree of significance for pre-
dicting mortality, which included patients requiring
help with feeding, the existence of malignancy (any ma-
lignancy including metastatic solid tumour), confusion,
low blood pressure, and age 40–64 years.
Patients requiring help with feeding were unable to
eat, needed assistance cutting food, spreading butter,
etc., and required a modified diet. Little is known
about the association between CAP mortality and in-
dependent feeding in CAP patients. Therefore, we
compared characteristics between patients who were
independent and those who required help with feeding
(Table 4). Patients who required help with feeding
were predominately male, were thinner, had a high
Charlson comorbidity index, and had a significant
lower activity than those who were independent with
feeding (P < 0.0001, all). Interestingly, aspiration pneu-
monia was a significantly predominant aetiology in pa-
tients who required help with feeding (P < 0.0001). In
addition, these patients’ pneumonia was more severe,
Table 3 Health care region organisational factors
30-day mortality
Factor No. of cases (%) Crude OR Adjusted ORa
(n = 49,370)) (95 % CI) (95 % CI)
Hospital volume (no. of beds)
≤ 200 7,373 (14.9) Reference Reference
201–600 31,868 (64.5) 1.2 (1.0–1.5) 1.0 (0.8–1.3)
≥ 601 10,129 (20.5) 1.7 (1.4–2.3) 1.2 (0.9–1.5)
Distance from the patients’ home to the hospital (km)
≤10 14,325 (29.0) Reference Reference
11–30 23,782 (48.2) 1.3 (1.1–1.5) 0.9 (0.8–1.1)
≥31 11,263 (22.8) 1.6 (1.3–1.9) 1.0 (0.8–1.2)
Weekend or holiday admission 10,237 (20.7) 1.3 (1.1–1.5) 1.1 (0.9–1.3)
Definition of abbreviations: OR odds ratio, CI confidence interval
aThe ORs were adjusted for all factors of patients’ characteristics, pneumonia characteristics, and health care region organisational factors. The c statistic for the
model is 0.89217




Characteristic (n = 40,442) (n = 8,928)
Personal characteristics
Female sex 18,194 (45.0) 3,106 (34.8)
Age, mean years ± SD 47.8 ± 13.8 50.2 ± 14.3
Body mass index, mean ± SD 22.0 ± 4.5 19.8 ± 5.4
Charlson comorbidity index, mean ± SD 0.9 ± 1.3 1.0 ± 1.3
Barthel index, mean ± SD 96.1 ± 11.6 15.1 ± 23.1
Pneumonia severitya
Mild 31,983 (79.1) 5,111 (57.3)
Moderate 8,239 (20.4) 3,473 (38.9)
Severe 175 (0.4) 236 (2.6)
Extremely severe 45 (0.1) 108 (1.2)
Pneumonia aetiologyb
Pneumococcal 3,789 (9.4) 603 (6.8)
Mycoplasmal 4,770 (11.8) 240 (2.7)
Aspiration 758 (1.9) 2,828 (31.7)
Influenza 137 (0.3) 30 (0.3)
Outcome after hospitalisation
Died within 30 days 252 (0.6) 480 (5.4)
Length of stay (days), mean ± SD 11.3 ± 14.0 26.2 ± 61.1
ICU admission 229 (0.6) 439 (4.9)
Definition of abbreviations: SD standard deviation, ICU intensive care unit
Data are n (%) of patients, unless noted otherwise
aThe pneumonia severity was evaluated using the A-DROP scoring system,
which assesses confusion, dehydration (the existence of a clinical sign of
dehydration or blood urea nitrogen level ≥210 mg/L), respiratory failure
(SpO2 ≤ 90 % or PaO2 ≤ 60 mmHg), and a low blood pressure (systolic blood
pressure ≤90 mmHg). Scoring: 0 =mild, 1–2 =moderate, 3 = severe, and
4 = extremely severe
bThe percentages are not equal to 100 % because other bacterial or viral and
unspecified bacterial pneumonia are excluded from this table
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and they stayed in the hospital longer and had a high
mortality (P < 0.0001, both).
Validation of the prediction rule
Table 5 shows regression results for 30-day death among
non-elderly patients with CAP using parameters of the
A-DROP and the newly proposed five risk factors. Most
ORs of the proposed score parameters were higher than
that of the A-DROP parameters. Figure 1 shows the
ROC curves for the new mortality risk score and A-
DROP score for non-elderly patients. The area under
the curve (AUC) for our method of predicting 30-day
mortality was 0.86 (95 % CI: 0.84–0.87). It was higher
than the AUC for the A-DROP score, which was 0.72
(95 % CI: 0.70–0.74) (P < 0.0001).
We also performed a comparison of the Kaplan-Meier
survival curves, as classified by the A-DROP score and
the new mortality risk score for non-elderly patients
(Fig. 2). In both survival curves, there were significant
differences between groups (P < 0.0001, both). Our
method identified groups that would not die in the hos-
pital compared to the A-DROP system, as observed in
comparison between the score 0 group of our method
and the score 0 group of the A-DROP score. Regarding
the ability to detect patients who would die in the hos-
pital, the proposed risk score more accurately detected a
group with high mortality than the A-DROP score. In
addition, the new risk score more clearly divided each
group with different mortalities because margins of mor-
tality between each group were larger in risk scores than
in A-DROP scores for non-elderly patients.
Table 6 shows patients’ characteristics for each mortality
risk score. There was a significant relationship between
the risk score and various characteristics, excluding influ-
enza pneumonia (almost P < 0.0001; influenza pneumonia,
P = 0.9158). Particularly, few patients died (only 2 died in
30 days) among 11,297 patients in the lowest risk score
(0). The negative likelihood ratio of the score 0 group
was 0.01 (95 % CI: 0.00–0.04) for 30-day death. The
positive likelihood ratio was 19.9 (95 % CI: 15.8–24.9)
for the score ≥4 group.
Table 5 Logistic regression for all non-elderly patients who died
within 30 days




Respiratory failured 2.1 (1.7–2.6)
Low blood pressuree 5.5 (4.7–6.4)
Parameters of the risk score for non-elderly patientsf
Requires help with feeding 7.1 (6.0–8.4)
Malignancyg 4.3 (3.6–5.0)
Confusion 3.0 (2.4–3.9)
Low blood pressuree 3.3 (2.8–3.9)
Age group, 40–64 yearsh 4.7 (3.4–6.7)
Definition of abbreviations: OR odds ratio, CI confidence interval
aThe ORs were adjusted for parameters of the A-DROP or risk score for
non-elderly patients
bAge was excluded from this table because all patients were <65 years. The c
statistic for the model is 0.73273
cThe existence of a clinical sign of dehydration or blood urea nitrogen
level ≥210 mg/L
dSpO2 ≤ 90 % or PaO2 ≤ 60 mmHg
eSystolic blood pressure ≤90 mmHg
fThe c statistic for the model is 0.86673
gAny malignancy including metastatic solid tumour
hThe reference group is 18–39 years
Fig. 1 Receiver operating characteristic curves for predicting 30-day
mortality of non-elderly patients with community-acquired pneumonia.
The risk score for non-elderly (range, 0–5) is calculated by summing
the existence of the following characteristics: patient requires help with
feeding; the existence of a malignancy (any malignancy including
metastatic solid tumour); confusion; low blood pressure (systolic blood
pressure ≤90 mmHg), and age 40–64 years. The A-DROP score
(range, 0–5) is obtained by summing the existence of the following
characteristics: confusion, dehydration (existence of a clinical sign
of dehydration or blood urea nitrogen level ≥210 mg/L), respiratory
failure (SpO2 ≤ 90 % or PaO2 ≤ 60 mmHg), a low blood pressure
(systolic blood pressure ≤90 mmHg), and age. For A-DROP, scores
for age are 0 points in all patients because all are <65 years. The
area under the curve of the risk score for non-elderly (0.86, 95 %
confidence interval [CI]: 0.84–0.87) is higher than that of the A-DROP
score (0.72, 95 % CI: 0.70–0.74) (P < 0.0001)
Tashiro et al. BMC Pulmonary Medicine  (2016) 16:39 Page 6 of 9
Discussion
Our new mortality risk scoring system had a greater abil-
ity for predicting death due to CAP in non-elderly adults.
Importantly, this system is easy to use in busy clinical set-
tings, and is based on patients’ independence with feeding,
the existence of a malignancy, confusion, low blood pres-
sure, and age. Clinicians can evaluate all of these parame-
ters before conducting laboratory tests. The existence of a
malignancy can be confirmed by patients’ medical history,
even though we cannot evaluate its existence in a case on
the initial visit. Regarding independence with feeding in
patients with CAP, any medical staff can evaluate this
quickly. Furthermore, the assigned points consist of only
one, and only five factors have to be assessed, which sim-
plify the mortality risk score calculation.
One of our study objectives was to create a new
method to prevent unnecessary over-treatment in non-
elderly patients with CAP who would survive. It has
been reported that only the PSI may be superior at iden-
tifying low-risk patients because it achieved a negative
likelihood ratio of <0.1, whereas the CURB-65 did not
[14]. Generally, a negative likelihood ratio of <0.1 is
regarded as necessary for a predictive or diagnostic test
to be considered robust [31]. In our study, the score 0
group among the new risk scores for non-elderly pa-
tients achieved a negative likelihood ratio of <0.1, but
the score ≤1 group did not. We found that patients in
the score 0 group would not die in 30 days.
In our study cohort, less than 15 % of patients with se-
vere disease according the risk score proposed were
admitted to ICU. In addition, only one patient was ad-
mitted in ICU in highest severity of pneumonia (Table 6).
The reason of a low ICU rate admission might be due to
the fact that the number of ICU beds was smaller in
Japan than other countries. Sasabuchi Y et al. reported
an ICU-to-hospital bed ratio in their study was relatively
small compared with those in Western countries [32].
Therefore some patients with severe disease in Japan
were obliged to admit to non-ICU beds.
In a similar study from Canada, Marrie et al. referenced
a limitation to their study [2]. They mentioned that their
study findings may not be generalisable to other countries.
Despite the fact that our study was conducted in Japan,
most of the findings were similar to theirs. We confirmed
that age, sex, and comorbidity were significantly associ-
ated with death in non-elderly patients, and patients with
aspiration pneumonia had a high mortality. In addition,
larger hospitals had higher case-fatality rates, but this was
more likely related to greater comorbidities and the se-
verity of pneumonia. Therefore, these features among
non-elderly patients may be similar worldwide. Another
limitation to their study was that they did not use the
data from a common severity index such as the PSI or
CURB-65. We were able to perform our analyses more
accurately since we used the A-DROP score.
There are several limitations to our study. First, we
could not compare the predictive ability of our new mor-
tality risk scoring system to that of the PSI. To detect low-
risk patients, a non-inferiority comparison between our
system and the PSI is needed. Second, a validation cohort
such as an outpatient population should confirm this
model in the future. Third, there may be several factors
associated with mortality that were not considered in this
study. For example, our study did not include factors such
as the results of laboratory tests, information on drugs
used to suppress the immune system, the use of anti-
bacterial agents before admission, a history of hospital
Fig. 2 Kaplan-Meier survival curves classified by the A-DROP score
and the risk score for non-elderly. The A-DROP score (range, 0–5) is
obtained by summing the existence of the following characteristics:
confusion, dehydration (existence of a clinical sign of dehydration
or blood urea nitrogen level ≥210 mg/L), respiratory failure (SpO2 ≤
90 % or PaO2 ≤ 60 mmHg), a low blood pressure (systolic blood
pressure ≤90 mmHg), and age. For A-DROP, scores for age are 0
points in all patients because all are <65 years. The risk score for
non-elderly (range, 0–5) is calculated by summing the existence of
the following characteristics: patient requires help with feeding;
the existence of malignancy (any malignancy including metastatic
solid tumour); confusion; low blood pressure (systolic blood pressure
≤90 mmHg), and age 40–64 years. In both survival curves, there are
significant differences for each group (P < 0.0001, all)
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admissions, or socioeconomic status. The income of
each individual, which was not included in this study,
would never affect the type of treatment because of the
universal health insurance coverage in Japan [33].
Fourth, we could not distinguish healthcare-associated
pneumonia from CAP, of which the clinical profile is
different from that of CAP [34]. Most patients who died
may be categorised as healthcare-associated pneumonia
because the analysis showed that the existence of a ma-
lignancy and reduction of Activities of Daily Living
were important risk factors. Fifth, there were several
limitations to the administrative databases. Rothberg et
al. reported that variation in the use of the principal
diagnosis of sepsis or respiratory failure might bias ef-
forts to compare hospital performance regarding pneu-
monia outcomes [35]. We may have missed severe
pneumonia patients with sepsis or respiratory failure
because the same phenomenon could have occurred in
this study.
Conclusion
Our newly proposed mortality risk scoring system may
be appropriate for predicting the mortality of non-
elderly patients with CAP. It showed the possibility of a
better prediction value than the A-DROP. Additionally,
it was easy to use in various clinical settings. Clinicians
should provide these patients with appropriate treatment
according to a precise mortality prediction.
Additional file
Additional file 1: Table S1. Definition of scores for each item of the
Barthel index used in this study. (DOCX 49.2kb)
Abbreviations
CAP: Community-acquired pneumonia; PSI: Pneumonia severity index;
DPC: Japanese diagnosis procedure combination; ICD-10: International
classification of diseases, tenth revision codes; ORs: Odds ratios;
Cis: Confidence intervals; ROC: Receiver operating characteristics.
Table 6 Comparison of characteristics in each group of risk score for non-elderly patients with community-acquired pneumonia
Risk score for non-elderly patientsa
Characteristic 0 1 2 3 4 5
No. of patients 11,297 (100.0) 23,670 (100.0) 10,926 (100.0) 3,099 (100.0) 354 (100.0) 24 (100.0)
Personal characteristics
Female sex 5,928 (52.5) 10,464 (44.2) 3,929 (36.0) 870 (28.1) 101 (28.5) 8 (33.3)
Age, mean years ± SD 30.0 ± 6.3 51.9 ± 11.4 56.0 ± 8.7 57.9 ± 6.6 59.1 ± 5.3 59.5 ± 5.5
Body mass index (kg/m2), mean ± SD 21.9 ± 4.7 21.9 ± 4.8 21.2 ± 4.9 20.1 ± 4.6 19.7 ± 4.3 18.1 ± 3.9
Charlson comorbidity index, mean ± SD 0.3 ± 0.6 0.7 ± 0.9 1.7 ± 1.6 1.9 ± 1.8 2.5 ± 2.0 3.5 ± 1.6
Barthel index, mean ± SD 97.7 ± 8.0 89.7 ± 25.4 63.1 ± 42.1 31.6 ± 38.9 16.4 ± 25.2 7.5 ± 16.5
Pneumonia severityb
Mild 10,485 (92.8) 19,996 (84.5) 6,294 (57.6) 319 (10.3) 0 (0.0) 0 (0.0)
Moderate 812 (7.2) 3,652 (15.4) 4,500 (41.2) 2,554 (82.4) 194 (54.8) 0 (0.0)
Severe 0 (0.0) 22 (0.1) 121 (1.1) 195 (6.3) 67 (18.9) 6 (25.0)
Extremely severe 0 (0.0) 0 (0.0) 11 (0.1) 31 (1.0) 93 (26.3) 18 (75.0)
Pneumonia aetiologyc
Pneumococcal 897 (7.9) 2,345 (9.9) 878 (8.0) 246 (7.9) 25 (7.1) 1 (4.2)
Mycoplasmal 2,813 (24.9) 1,799 (7.6) 362 (3.3) 35 (1.1) 1 (0.3) 0 (0.0)
Influenza 41 (0.4) 79 (0.3) 33 (0.3) 12 (0.4) 2 (0.6) 0 (0.0)
Aspiration 59 (0.5) 860 (3.6) 1,720 (15.7) 855 (27.6) 86 (24.3) 6 (25.0)
Outcome after hospitalisation
Died within 30 days 2 (0.0) 88 (0.4) 270 (2.5) 285 (9.2) 76 (21.5) 11 (45.8)
Length of stay (days), mean ± SD 8.0 ± 5.6 12.1 ± 17.7 18.8 ± 29.1 30.2 ± 70.9 37.3 ± 155.3 29.2 ± 36.6
ICU admission 30 (0.3) 160 (0.7) 263 (2.4) 181 (5.8) 33 (9.3) 1 (4.2)
Definition of abbreviations: SD standard deviation
Data are n (%) of patients, unless noted otherwise
aEach risk factor (requires help with feeding, malignancy, confusion, low blood pressure, and age 40–64) receives one point. A total point score for each patient is
obtained by summing the points
bThe pneumonia severity was evaluated using the A-DROP scoring system, which assesses confusion, dehydration (the existence of a clinical sign of dehydration
or blood urea nitrogen level ≥210 mg/L), respiratory failure (SpO2 ≤ 90 % or PaO2 ≤ 60 mmHg), and a low blood pressure (systolic blood pressure ≤90 mmHg).
Scoring: 0 =mild, 1–2 =moderate, 3 = severe, and 4 = extremely severe
cThe percentages are not equal to 100 % because other bacterial or viral and unspecified bacterial pneumonia are excluded from this table
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